IDEX Biometrics ASA
IDBA · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.82 | -2.03 | 20.31 | 2.13 |
| FCF Yield | -0.00% | -0.39% | -0.53% | -0.33% |
| EV / EBITDA | 863.39 | -265.70 | -295.08 | -265.78 |
| Quality | ||||
| ROIC | -33.81% | -42.76% | -27.49% | -20.17% |
| Gross Margin | -2,423.33% | 39.48% | -912.90% | -731.24% |
| Cash Conversion Ratio | -1.67 | 0.76 | 1.26 | 0.79 |
| Growth | ||||
| Revenue 3-Year CAGR | -29.88% | -15.57% | 0.50% | 13.37% |
| Free Cash Flow Growth | 100.00% | 22.85% | -57.99% | 39.96% |
| Safety | ||||
| Net Debt / EBITDA | 1.05 | -0.43 | -1.22 | 0.19 |
| Interest Coverage | -6.83 | -10.86 | -9.65 | -151.51 |
| Efficiency | ||||
| Inventory Turnover | 0.24 | 0.04 | 0.57 | 0.66 |
| Cash Conversion Cycle | 3,045.75 | 2,351.32 | 482.75 | 294.37 |